What is Accelerate Diagnostics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Accelerate Diagnostics's interest expense for the
three
months ended in Mar. 2024 was $ -2.45 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.76 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Accelerate Diagnostics's Operating Income for the
three
months ended in Mar. 2024 was $ -10.16 Mil. Accelerate Diagnostics's Interest Expense for the
three
months ended in Mar. 2024 was $ -2.45 Mil.
Accelerate Diagnostics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Accelerate Diagnostics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics (NAS:AXDX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Accelerate Diagnostics's Interest Expense for the
three
months ended in Mar. 2024 was $-2.45 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-10.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $38.06 Mil.
Accelerate Diagnostics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Accelerate Diagnostics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Accelerate Diagnostics (Accelerate Diagnostics) Business Description
Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
| David Patience |
officer: Chief Financial Officer |
C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714 |
| Jack Phillips |
director, officer: PRESIDENT AND CEO |
11731 YALE DR, CARMEL IN 46032 |
| Larry Michael Mertz |
officer: Chief Technology Officer |
3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714 |
| Marran H. Ogilvie |
director |
599 LEXINGTON AVENUE, NEW YORK NY 10022 |
| Jennifer Regan |
director |
C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
| Mark S. Black |
director |
3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
| Steven Reichling |
officer: CFO |
7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221 |
| Ron Price |
officer: SVP & HEAD OF COM OPS AMERICAS |
3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
| Wayne Burris |
director |
3451 PLANO PARKWAY, LEWISVILLE TX 75056 |
| Hany Massarany |
director |
1910 INNOVATION PARK DR, TUCSON AZ 85737 |
| Jack W Schuler |
director, 10 percent owner |
100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
| Mark C Miller |
director |
C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045 |
| Ten Brink Frank Jm |
director |
C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045 |
| Charles M Watts |
director |
3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714 |
| Louise Francesconi |
director |
870 WINTER STREET, WALTHAM MA 02451 |
Accelerate Diagnostics (Accelerate Diagnostics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AXDX has been successfully added to your 